Abstract | PURPOSE: PATIENTS AND METHODS: Patients were randomly assigned in a 2:1 ratio to receive trabectedin or dacarbazine intravenously every 3 weeks. The primary end point was overall survival (OS), secondary end points were disease control-progression-free survival (PFS), time to progression, objective response rate, and duration of response-as well as safety and patient-reported symptom scoring. RESULTS: A total of 518 patients were enrolled and randomly assigned to either trabectedin (n = 345) or dacarbazine (n = 173). In the final analysis of PFS, trabectedin administration resulted in a 45% reduction in the risk of disease progression or death compared with dacarbazine (median PFS for trabectedin v dacarbazine, 4.2 v 1.5 months; hazard ratio, 0.55; P < .001); benefits were observed across all preplanned subgroup analyses. The interim analysis of OS (64% censored) demonstrated a 13% reduction in risk of death in the trabectedin arm compared with dacarbazine (median OS for trabectedin v dacarbazine, 12.4 v 12.9 months; hazard ratio, 0.87; P = .37). The safety profiles were consistent with the well-characterized toxicities of both agents, and the most common grade 3 to 4 adverse effects were myelosuppression and transient elevation of transaminases in the trabectedin arm. CONCLUSION:
|
Authors | George D Demetri, Margaret von Mehren, Robin L Jones, Martee L Hensley, Scott M Schuetze, Arthur Staddon, Mohammed Milhem, Anthony Elias, Kristen Ganjoo, Hussein Tawbi, Brian A Van Tine, Alexander Spira, Andrew Dean, Nushmia Z Khokhar, Youn Choi Park, Roland E Knoblauch, Trilok V Parekh, Robert G Maki, Shreyaskumar R Patel |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 34
Issue 8
Pg. 786-93
(Mar 10 2016)
ISSN: 1527-7755 [Electronic] United States |
PMID | 26371143
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2015 by American Society of Clinical Oncology. |
Chemical References |
- Antineoplastic Agents, Alkylating
- Dioxoles
- Tetrahydroisoquinolines
- Dacarbazine
- Trabectedin
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Alkylating
(administration & dosage, adverse effects)
- Dacarbazine
(administration & dosage, adverse effects)
- Dioxoles
(administration & dosage, adverse effects)
- Disease-Free Survival
- Drug Administration Schedule
- Female
- Humans
- Leiomyosarcoma
(drug therapy)
- Liposarcoma
(drug therapy)
- Male
- Middle Aged
- Survival Rate
- Tetrahydroisoquinolines
(administration & dosage, adverse effects)
- Trabectedin
- Young Adult
|